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Objective: To assess short-term outcomes after minimally invasive (laparo-
scopic, robot-assisted, and hybrid) pancreatoduodenectomy (MIPD) versus
open pancreatoduodenectomy (OPD) among European centers.
Background: Current evidence on MIPD is based on national registries or
single expert centers. International, matched studies comparing outcomes for
MIPD and OPD are lacking.
Methods: Retrospective propensity score matched study comparing MIPD in
14 centers (7 countries) performing10MIPDs annually (2012–2017) versus
OPD in 53German/Dutch surgical registry centers performing 10 OPDs
annually (2014–2017). Primary outcome was 30-day major morbidity (Clav-
ien-Dindo 3).
Results: Of 4220 patients, 729/730 MIPDs (412 laparoscopic, 184 robot-
assisted, and 130 hybrid) were matched to 729 OPDs. Median annual case-
volume was 19 MIPDs (interquartile range, IQR 13–22), including the first
MIPDs performed in 10/14 centers, and 31 OPDs (IQR 21–38). Major
morbidity (28% vs 30%, P ¼ 0.526), mortality (4.0% vs 3.3%, P ¼
0.576), percutaneous drainage (12% vs 12%, P ¼ 0.809), reoperation
(11% vs 13%, P ¼ 0.329), and hospital stay (mean 17 vs 17 days, P >
0.99) were comparable between MIPD and OPD. Grade-B/C postoperative
pancreatic fistula (POPF) (23% vs 13%, P< 0.001) occurred more frequently
after MIPD. Single-row pancreatojejunostomy was associated with POPF in
MIPD (odds ratio, OR 2.95, P< 0.001), but not in OPD. Laparoscopic, robot-
assisted, and hybrid MIPD had comparable major morbidity (27% vs 27% vs
35%), POPF (24% vs 19% vs 25%), and mortality (2.9% vs 5.2% vs 5.4%),
with a fewer conversions in robot-assisted- versus laparoscopic MIPD (5% vs
26%, P < 0.001).
Conclusions: In the early experience of 14 European centers performing10
MIPDs annually, no differences were found in major morbidity, mortality, and
hospital stay between MIPD and OPD. The high rates of POPF and conver-
sion, and the lack of superior outcomes (ie, hospital stay, morbidity) could
indicate that more experience and higher annual MIPD volumes are needed.
Keywords: hybrid, laparoscopic, minimally invasive, pancreas, pancreatic
cancer, pancreatic tumors, propensity score matching, robot, robotic, surgery,
Whipple
(Ann Surg 2020;271:356–363)
P ancreatoduodenectomy is associated with high morbidity ratesand a strong volume-outcome relationship.1–3 Minimally inva-
sive pancreatoduodenectomy (MIPD; laparoscopic, robot-assisted,
or hybrid) could reduce morbidity and enhance postoperative recov-
ery compared with open pancreatoduodenectomy (OPD),1,2,4–12 but
its implementation is lagging compared with minimally invasive
distal pancreatectomy.13,14
Two factors may have delayed the implementation of MIPD.
First, pancreatoduodenectomy is a demanding procedurewith several
anastomoses and potentially life-threatening complications. Indeed,
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MIPD has been associated with increased perioperative mortality
compared with OPD in centers performing a fewer than 10 MIPDs
annually.15,16 Moreover, improved outcomes in centers performing
more than 40 OPDs annually could indicate that the optimal volume
cut-off for MIPD is also (much) higher.17 Second, current evidence
on the effectiveness and safety of MIPD consists mainly of registry
studies with a large proportion of low-volume centers14–16,18 or
small-/single center retrospective studies from high-volume centers,
suffering from reporting bias and/or insufficient adjustment for
confounding by indication (surgical case selection).1,8 The only
published randomized trial on laparoscopic MIPD versus OPD
(PLOT: Pancreatic Head and Periampullary Cancer Laparoscopic
versus Open Surgical Treatment; NCT02081131) reported shorter
length of hospital stay after MIPD but was underpowered to demon-
strate a benefit regarding major morbidity.19 Large multicenter
(matched) studies on MIPD versus OPD are lacking.
The purpose of this study was to combine data from European
centers performing at least 10 MIPDs annually in a multicenter
propensity score matched cohort study on MIPD versus OPD. We
hypothesized that MIPD is associated with equivalent morbidity and
mortality compared with OPD, when performed in such centers, but
with superior secondary outcomes (eg, shorter length of stay).
METHODS
We performed a retrospective multicenter propensity score
matched cohort study comparing MIPD cases to OPD controls.
MIPD patients were included from European centers performing
at least 10 MIPDs per year. OPD patients were included from centers
performing at least 10 OPDs per year in 2 Dutch and German surgical
registries. This study was initiated by the European Consortium on
Minimally Invasive Pancreatic Surgery (E-MIPS) and supported by
the Scientific and Research Committee of the European-African
Hepato-Pancreato-Biliary Association (E-AHPBA). We used the
STROBE guidelines20 for design and reporting of the study, which
included registration of a study protocol at clinicaltrials.gov
(NCT03172572). Need for ethical approval was waived by the
institutional review board at the Academic Medical Center in
Amsterdam.
Eligibility and Data Collection
Inclusion criteria were electiveMIPD (including laparoscopic,
robot-assisted, or hybrid procedures) or OPD in adults, for solid
premalignant tumors or cysts. Hybrid was defined as laparoscopic
resection and open reconstruction via (limited) laparotomy. Exclu-
sion criteria were chronic pancreatitis as indication for surgery,
arterial resection, insufficient baseline data, or missing primary
outcome data.
Included cases were consecutive patients undergoing elective
MIPD between January 1, 2012 and July 31, 2017 at participating E-
AHPBA and E-MIPS centers. Each center appointed a local study
coordinator responsible for data collection and communication with
the central study coordinators (SK and JH). All data was collected via
an International Conference on Harmonization Good Clinical Prac-
tice (ICH-GCP) compliant on-line electronic case report form
(eCRF) and data storage environment (CASTOR, CIWIT B.V.,
Amsterdam, the Netherlands). In addition, local study coordinators
completed a survey (Google Survey, Mountain View, CA) with
questions regarding methods of data collection, annual case volume,
standard of care, and surgical case selection.
Included controls were consecutive patients undergoing OPD
between January 1, 2014 and July 31, 2017 who were registered in
the nationwide German Society for General and Visceral Surgery
(DGAV) Studien-, Dokumentations- und Qualita¨tszentrum (Stu-
DoQjPancreas),21 and the Dutch Pancreatic Cancer Audit (DPCA)22
registries. All centers were blinded to maintain anonymity on out-
comes and prevent reporting bias.
Primary and Secondary Outcomes
The primary outcome was 30-day major morbidity (Clavien-
Dindo 3a-5).23 Secondary outcomes were 30-day mortality, grade-B/
C pancreatic fistula (POPF), grade B/C postpancreatectomy hemor-
rhage (PPH), and length of hospital stay (day of surgery to day of
discharge).
Definitions
Preoperative variables included baseline characteristics, such
as age, sex, body-mass-index (BMI), and comorbidities (Charlson
Comorbidity Index24), surgical history, computed tomography/mag-
netic resonance imaging (CT/MRI)-scan information (vascular/
organ involvement), American Society of Anesthesiologists (ASA)
classification25, and Eastern Cooperative Oncology Group (ECOG)
performance status. Conversion was recorded if a robot-assisted or
laparoscopic MIPD was converted to OPD. The International Study
Group on Pancreatic Surgery (ISGPS) 2005 definition26 was used to
classify POPF. Although a newer definition is available,27 it was not
used in the registry data and could therefore not be applied to
compare outcomes. The ISGPS and International Study Group of
Liver Surgery (ISGLS) definitions were used to classify delayed
gastric emptying,28 PPH,29 and bile leakage.30 Surgical site infec-
tions were defined using the Center for Disease Control and Preven-
tion (CDC) definition.31 All complications (minor or major)
occurring during the initial hospitalization and subsequent readmis-
sions were recorded. Patient were followed-up until discharge or
30 days postoperatively (whichever occurred later) in the German
and Dutch registries and until the last hospital visit or phone call in
the MIPD centers. Therefore, all primary and secondary outcomes in
this study are limited to in-hospital or 30-day events.
Propensity Score Matching
Propensity score matching was applied to achieve a balanced
exposure groups at baseline (ie, minimal confounding), in accor-
dance with the recommendations by Lonjon et al.32 The probability
to undergo MIPD for each patient (ie, the propensity score) was
obtained from a logistic regression model. The study entry survey
was used to ensure all reported MIPD selection factors were included
as covariates in the model to further reduce potential confounding by
indication. Final covariates were age, sex, BMI, ASA, Charlson
comorbidity index, ECOG, tumor location (pancreas vs periampul-
lary/ distal common bile duct vs duodenum), suspected malignancy,
organ involvement on imaging, multivisceral resection, porto-mesen-
teric vein resection, and pancreatic texture (Supplement 1, http://
links.lww.com/SLA/B435). MIPD cases were analyzed intention-to-
treat, regardless of conversion to open surgery, and matched in a 1:1
ratio to OPD controls based on the propensity score with a standard
caliper width of 0.2.
Sensitivity Analyses
The association between treatment group (exposure) and
primary and secondary outcomes was measured using odds ratios.
A first sensitivity analysis assessed the impact of volume, learning
curve, hybrid surgery, conversions, and laparoscopy. This was done
using multivariable-adjusted odds ratios after respective exclusion of
centers performing 10 to 20 MIPDs per year, the first 20 MIPD cases
at each center, hybrid procedures, hybrid and converted procedures,
and hybrid and laparoscopic procedures. A second sensitivity analy-
sis was performed to mitigate differences in postoperative t-stage,
histopathological diagnosis, and pancreatic duct diameter by replac-
ing preoperative diagnosis by histological diagnosis, and by
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including tumor stage and duct diameter in the propensity score
model. A third analysis assessed baseline-, tumor-, and perioperative
characteristics to identify new risk factors for POPF after MIPD,
using multivariable logistic regression based on a univariable screen
(P < 0.1) and backward stepwise elimination (if P > 0.05 and
clinically irrelevant).
Statistics
Missing baseline and outcome data were resolved using
chained multiple imputation33, which reduces bias in combination
with propensity score matching.32 Categorical data were reported as
proportions and continuous data as mean and standard deviation (SD)
or median and interquartile range (IQR) as appropriate. We used the
standardized mean difference (SMD) to assess balance at baseline in
both groups. Optimal balance on a parameter is generally achieved
when the SMD is on or below 0.1. To test for statistical significance
(alpha 0.05), we used the Fisher exact test for categorical variables,
and the student t-test for continuous variables (applying the central
limit theorem). All confidence intervals (CI) were 95%. All data were
handled and analyzed using IBM SPSS Statistics for Windows
version 23.0 (IBM Corp., Orchard Road Armonk, New York,
NY), STATA version 14.1 (StataCorp LP, College Station, TX), or
R’s programming environment (R Foundation for Statistical Com-
puting, Vienna, Austria).
RESULTS
We identified 903 MIPD patients from 26 E-AHPBA and
E-MIPS centers and 4020 OPD patients from 70 German and Dutch
centers. After exclusions, 730 MIPD patients from 14 E-MIPS
centers and 3490 OPD patients from 53 high-volume DGAV and
DPCA centers were included (see Fig. 1). Of all 14 MIPD centers, 7
performed laparoscopic, 4 both hybrid and laparoscopic, and 3 robot-
assisted MIPD. The median annual pancreatoduodenectomy (MIPD
and OPD combined) volume was 41 (IQR 17–69) among the MIPD
centers and 31 (IQR 21–38) among the OPD centers. The median
annualMIPD volumewas 19 (13–22), which included the firstMIPD
case performed in 10 of 14 (71%) centers. Of all included patients,
729 of 730 MIPD cases could be matched (1:1) to an OPD control
(Fig. 1).
Selecting Patients for MIPD
Reported selection factors for MIPD were absence of vascular
involvement (11 of 14 MIPD centers), smaller or periampullary
tumors (7 of 14), absence of chronic pancreatitis (4 of 14), BMI
35 (3 of 14), low risk of POPF (1 of 14), absence of arterial
involvement (1 of 14), and availability of minimally invasive equip-
ment (1 of 14) (Fig. 2). One center indicated that MIPD selection
factors had been stricter during the initial learning curve phase. The
observed selection factors and their odds ratios are presented in
Supplement 1, http://links.lww.com/SLA/B435, propensity score
distributions in Supplement 2, http://links.lww.com/SLA/B435.
903 MIPD (E-MIPS)
2012 – 2017
1720 OPD (DPCA)
2014 – 2017
2300 OPD (DGAV-StuDoQ)
2014 – 2016
Excluded
252 Annual volume <10 MIPD or OPD
150 Indicaon: chronic pancreas
106 Arterial resecon
184 Insufficient baseline data
11 Missing primary outcome
729 OPD729 MIPD
412 Laparoscopic
187 Robot-assisted
130 Hybrid
Before matching
N=4220
Inclusion/ 
selecon
Exposure
218 Endpoint occurred206 Endpoint occurred
30-day
Follow-up
Propensity score match 
(rao 1:1, caliper 0.2)
N=1460
FIGURE 1. Study Flow-Chart. Endpoint was 30-day major morbidity. Annual indicates annual; DPCA, Dutch Pancreatic Cancer
Audit; DGAV StuDoQ, German Society for General and Visceral Surgery Studien-, Dokumentations- und Qualita¨tszentrum; E-MIPS,
European consortium on Minimally Invasive Pancreatic Surgery.
BMI < 35
No chronic pancreatitis
Low POPF Risk
Favoring smaller lesions
Favoring periampullary lesions
No vascular involvement (any)
No arterial involvement
Availability of equipment
2
4
6
8
10
12
14
FIGURE 2. Self-reported Surgical Selection Factors for MIPD.
Institutional or patient-related factors used by the 14 partici-
pating E-MIPS centers to select patients for MIPD. MIPD indi-
cates minimally invasive pancreatoduodenectomy; POPF,
postoperative pancreatic fistula.
Klompmaker et al Annals of Surgery  Volume 271, Number 2, February 2020
358 | www.annalsofsurgery.com  2019 Wolters Kluwer Health, Inc. All rights reserved.
 Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Baseline Characteristics
See Table 1 for baseline characteristics before and after
matching. Almost all baseline variables were more balanced after
propensity score matching. Some differences remained as a result of
the matching by preoperative (and not postoperative) variables; the
MIPD group had a fewer pathologic T-stage 3 tumors (37% vs 49%,
SMD –0.23), smaller tumors (26mm vs 30mm, SMD –0.26), and a
fewer N1-tumors (45% vs 59%, SMD –0.28) compared with the
OPD group. However, the malignant lymph node ratio (0.1 vs 0.1,
SMD –0.10) was similar between groups. Of note, among the 638
patients with reported pancreatic duct measurement (44% missing),
the mean duct size was slightly larger in the OPD group (5mm vs
6mm, SMD –0.20).
Primary and Secondary Outcomes
See Table 2 for outcomes before and after matching. The
MIPD group had longer operative times [mean 416 (SD 111) vs 330
(SD 103) minutes, P < 0.001] and more pancreatogastrostomies
(19% vs 13%, P < 0.002). Rates of routine intraoperative drain
placement were similar (91% vs 94%) between MIPD and OPD. In
the MIPD group, 115 of 729 (15.8%) procedures were converted
from laparoscopic (26%) or robot-assisted (5%, P< 0.001) MIPD to
OPD, see Supplement 3, http://links.lww.com/SLA/B435. The rates
of major morbidity (28% vs 30%, P¼ 0.526) and mortality (4.0% vs
3.3%, P ¼ 0.576) were similar between MIPD and OPD. The rate of
grade B/C POPF (23% vs 13%, P < 0.001) was higher after MIPD.
The rate of grade B/C bile leakage was slightly lower after MIPD
TABLE 1. Baseline Characteristics Before and After Propensity Score Matching
Baseline
OPD Prematch
N ¼ 3490
OPD Postmatch
N ¼ 729
MIPD
N ¼ 729
Standard
Difference Prematch
Standard
Difference Postmatch
Age, mean (SD), y 66.9 (10.7) 64.6 (11.7) 64.5 (11.6) 0.21 0.00
BMI, mean (SD), kg/m2 25.7 (10.0) 24.8 (4.0) 24.9 (4.2) 0.11 0.02
Charlson comorbidity index, median (IQR) 0.6 (.9) 0.5 (.9) 0.5 (.9) 0.06 0.02
Female sex (n), % 1512 (43.3) 363 (49.8) 357 (49.0) 0.11 0.02
ASA-classification (n), %
ASA 1 336 (9.6) 154 (21.1) 139 (19.1) 0.27 0.06
ASA 2 1855 (53.2) 416 (57.1) 421 (57.8) 0.09 0.01
ASA 3-4 1275 (36.5) 149 (20.4) 162 (22.2) 0.32 0.04
ASA Unknown 24 (.7) 10 (1.4) 7 (1.0)
ECOG performance status (n), %
ECOG 0-1 3116 (89.3) 667 (91.5) 614 (84.2) 0.15 0.21
ECOG 2 130 (3.7) 31 (4.3) 36 (4.9) 0.06 0.03
ECOG 3-4 133 (3.8) 5 (.7) 5 (.7) 0.21 0.00
ECOG Unknown 111 (3.2) 26 (3.6) 74 (10.2)
Preoperative tumor characteristics
Localization (n), %
Pancreas 2208 (63.3) 453 (62.1) 458 (62.8) 0.01 0.01
Periampullary or CBD 466 (13.4) 76 (10.4) 101 (13.9) 0.01 0.10
Duodenum 187 (5.4) 39 (5.3) 36 (4.9) 0.01 0.02
Unknown 446 (12.8) 121 (16.6) 112 (15.4) 0.07 0.04
Malignant indication (n), % 2474 (72.5) 453 (63.6) 451 (62.2) 0.22 0.03
Neoadjuvant treatment (n), % 69 (2.0) 7 (1.0) 7 (1.0) 0.08 0.00
Unknown 1 (.0) 19 (2.6)
Preoperative tumor size, mean (SD), mm 27.5 (20.3) 28.9 (26.8) 26.4 (13.9) 0.06 0.14
Unknown 2692 (77.1) 521 (71.5) 264 (36.2)
Pathology
Histology (n), %
Adenocarcinoma - pancreas 1690 (48.4) 345 (47.3) 307 (42.1) 0.13 0.10
Adenocarcinoma - duodenum 149 (4.3) 23 (3.2) 14 (1.9) 0.14 0.07
Adenocarcinoma - other 769 (22.0) 165 (22.6) 132 (18.1) 0.10 0.11
NET 167 (4.8) 45 (6.2) 52 (7.1) 0.10 0.04
IPMN/MCN 226 (6.5) 50 (6.9) 81 (11.1) 0.16 0.15
Chronic pancreatitis 94 (2.7) 19 (2.6) 14 (1.9) 0.05 0.05
Intestinal adenoma 104 (3.0) 23 (3.2) 22 (3.0) 0.00 0.01
Other 269 (7.7) 56 (7.7) 100 (13.7)
Unknown 22 (.6) 3 (.4) 7 (1.0)
T-stage (n), %
Not adenocarcinoma 882 (25.3) 196 (26.9) 276 (37.9) 0.27 0.24
Tis-T2 424 (12.1) 95 (13.0) 142 (19.5) 0.20 0.18
T3 1797 (51.5) 355 (48.7) 273 (37.4) 0.29 0.23
T4 137 (3.9) 35 (4.8) 19 (2.6) 0.07 0.12
Unknown 250 (7.2) 48 (6.6) 19 (2.6)
Tumor size, mean (SD), mm 29.4 (17.3) 29.9 (18.5) 25.9 (13.9) 0.22 0.26
N-stage 1 (n), % 1764 (57.3) 382 (59.3) 305 (45.3) 0.24 0.28
Lymph node ratio, mean (SD) 0.1 (.2) 0.1 (.2) 0.1 (.2) 0.10 0.10
M-stage 1 (n), % 112 (3.4) 19 (2.8) 10 (1.5) 0.12 0.09
ASA indicates American Society of Anesthesiologists; BMI, body mass index; CBD, common bile duct; ECOG, Eastern Cooperative Oncology Group; IPMN, intraductal papillary
mucinous neoplasm; IQR, interquartile range; MCN, mucinous cystic neoplasm; MIPD, minimally invasive pancreatoduodenectomy; NET, neuroendocrine tumor; OPD, open
pancreatoduodenectomy.
Pancreatic ductal-, duodenum-, distal bile duct-, or other type.
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(3.0% vs 5.1%, P¼ 0.047). However, the overall rates of endoscopic
reintervention (3.7% vs 2.2%, P ¼ 0.068), percutaneous catheter
drainage (12% vs 12%, P ¼ 0.809), reoperation (11% vs 13%, P ¼
0.329), and intensive care unit admission (6.3% vs 6.5%, P ¼ 0.500)
were similar between MIPD and OPD.
Lengths of hospital stay [mean 18 (SD 20) vs 17 (SD 15) days
and median 14 vs 13 days, P< 0.001] were significantly longer in the
MIPD group. As expected through variation in discharge policy
between countries, there was a considerable difference in hospital
stay after MIPD between 7 Belgian/Dutch/German (mean 16, median
13 days) and 5 French/Italian (mean 23, median 17 days) centers.
When comparing MIPD versus OPD in Dutch and German centers,
no differences in hospital stay were found [mean 17 (SD 12) vs 17
(SD 15) days – median 13 vs 14 days, P > 0.99]. Equally, no
significant differences were found after excluding all patients with
grade B/C POPF [mean 15 (SD 11) vs 15 (SD 10) days – median 12
vs 13 days, P ¼ 0.389].
Sensitivity Analyses
MIPD was not associated with major morbidity before (odds
ratio, OR 0.85, P ¼ 0.072) or after (OR 0.92, P ¼ 0.489) propensity
score matching. MIPD was also not associated with 30-day mortality
before (OR 1.03, P ¼ 0.869) or after (OR 1.36, P ¼ 0.269), but there
was an association with POPF before (OR 1.87, P < 0.001) and after
propensity score matching (OR 2.01, P < 0.001). These estimations
remained stable across all sensitivity analysis scenarios (Fig. 3, Sup-
plement 4, http://links.lww.com/SLA/B435). Between laparoscopic,
robot-assisted and hybrid procedures, the unadjusted rates of major
morbidity (27%vs 27%vs 35%), POPF (24%vs 19%vs 25%), and 30-
day mortality (2.9% vs 5.2% vs 5.4%)were similar, see Supplement 3,
http://links.lww.com/SLA/B435. Volume-outcome associations for
major morbidity and POPF are presented in Supplement 5, http://
links.lww.com/SLA/B435.
In a second sensitivity analysis (n ¼ 600), adding pancreatic
duct diameter, histopathological diagnosis, and T-stage as propensity
score matching variables, MIPD was not associated with increased
30-day major morbidity (OR 1.11, P¼ 0.581) or mortality (OR 1.61,
P ¼ 0.253), and the association with POPF (OR 1.53, P ¼ 0.087)
remained similar.
In a third analysis comparing MIPD patients with- (n ¼ 164)
and without (n¼ 563) POPF, some known and new risk factors were
identified, see Supplement 6A, http://links.lww.com/SLA/B435.
After multivariable adjustment, the most important newly identified
risk factor for POPF in MIPD was single-row pancreatojejunostomy
(OR 2.95, P < 0.001) as opposed to double-row pancreatojejunos-
tomy or pancreatogastrostomy, see Supplement 6B, http://links.
lww.com/SLA/B435. In patients with OPD, no association between
single-row pancreatojejunostomy and POPF was found.
DISCUSSION
This large pan-European propensity score matched cohort
study in centers performing at least 10 MIPDs per year found no
differences in 30-day major morbidity, mortality, and length of stay
between MIPD and OPD. However, MIPD was associated with a
TABLE 2. Outcomes Before and After Propensity Score Matching
Perioperative
OPD Prematch
N ¼ 3490
OPD Postmatch
N ¼ 729
MIPD
N ¼ 729 P
Operative time, median (SD), min 328.4 (99.6) 324.2 (93.9) 415.8 (110.9) <0.001
Median (IQR) 316 (259–382) 312 (255–377) 400 (330–487)
Type of resection (n), %
Pylorus preserving pancreatoduodenectomy 2289 (65.6) 501 (68.7) 481 (66.0) 0.289
Classic Whipple 1201 (34.4) 228 (31.3) 240 (32.9) 0.537
Additional organs resected(n), % 294 (8.4) 19 (2.6) 17 (2.3) 0.866
Unknown 94 (2.7) 17 (2.3) 10 (1.4)
Veins resected(n), % 423 (12.1) 71 (9.7) 64 (8.8) 0.588
Unknown 20 (.6) 5 (.7) 10 (1.4)
Type of anastomosis (n), %
Pancreatojejunostomy 2886 (82.7) 612 (84.0) 548 (75.2) <0.001
Pancreatogastrostomy 456 (13.1) 92 (12.6) 136 (18.7) 0.002
Other 148 (4.2) 25 (3.4) 45 (6.2)
Hard/firm pancreas 1038 (29.7) 243 (33.3) 255 (35.0) 0.544
Unknown 623 (17.9) 116 (15.9) 107 (14.7)
Postoperative (30 days)
Morbidity (n), %
Clavien-Dindo 0–2 (none or minor) 2382 (68.3) 511 (70.1) 523 (71.7) 0.526
Clavien-Dindo 3a–4b (major) 958 (27.4) 194 (26.6) 177 (24.3) 0.336
Clavien-Dindo 5 (death) 150 (4.3) 24 (3.3) 29 (4.0) 0.576
Pancreatic fistula grade B/C (n), % 469 (13.5) 92 (12.7) 164 (22.6) <0.001
Bile leakage grade B/C (n), % 160 (4.6) 37 (5.1) 22 (3.0) 0.047
Hemorrhage grade B/C (n), % 274 (7.9) 53 (7.3) 69 (9.5) 0.156
Delayed gastric emptying grade B/C (n), % 475 (13.6) 95 (13.1) 77 (10.6) 0.167
Reoperation (n), % 449 (13.1) 90 (12.6) 80 (11.0) 0.329
Length of hospital say, mean (SD), d 18.8 (14.6) 17.4 (14.6) 18.2 (19.5) <0.001
Median (IQR) 14 (11–21) 13 (10–19) 14 (9–21)
German and Dutch centers only 18.8 (14.6) 17.4 (14.6) 17.0 (12.3) >0.99
Median (IQR) 14 (11–21) 13 (10–19) 14 (9–20)
Unplanned readmission (n), % 402 (11.8) 90 (12.6) 69 (9.8) 0.11
Other than pancreatic head, duodenum, gallbladder, or pylorus.
Such as porto-mesenteric vein, superior mesenteric vein.
P-value for the difference between OPD and MIPD after propensity-score matching.
IQR indicates interquartile range; MIPD, minimally invasive pancreatoduodenectomy; OPD, open pancreatoduodenectomy.
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10% higher rate of grade B/C POPF and longer (90minutes) opera-
tive times, but no increase in bile leakage. These results remained
similar after excluding, respectively, centers performing 10 to 20
MIPDs per year, the first 20 MIPD procedures per center, hybrid
procedures, conversions, and hybrid and laparoscopic procedures.
No differences in risk of major morbidity, mortality, and POPF were
observed between laparoscopic, robot-assisted, and hybrid MIPD,
but the conversion rate was lower after robot-assisted- versus lapa-
roscopic MIPD (5% vs 26%). Single-row pancreatojejunostomy was
a newly identified risk factor for POPF in MIPD.
In keeping with these findings, 2 recent systematic reviews
comparing MIPD versus OPD found no difference in 30-day mor-
tality, but increased operative times after MIPD.1,8 In contrast to our
findings, these studies found similar rates of POPF, lower rates of
delayed gastric emptying, and shorter hospital stays after MIPD. One
review also found fewer postoperative complications and a lower rate
of delayed gastric emptying after robot-assisted- versus laparoscopic
MIPD. As was noted in one of the reviews, considerable publication
bias has likely influenced these positive results for MIPD.1 Two US
nationwide registry studies on MIPD versus OPD for pancreatic
ductal adenocarcinoma found higher rates of 30-day mortality in
centers performing a fewer than 10 MIPDs annually, compared with
equivalent rates in higher volume centers.15,16 Two other registry
studies on MIPD versus OPD found that laparoscopic MIPD was
associated with lower rates of overall complications and shorter
hospital stays.14,18 Shorter hospital stays were also reported by the
recent PLOT trial including 64 patients.19 The absence of a clinical
benefit of MIPD in the current study is an important finding.
However, given the current early experience and relatively low
annual volume of MIPD in most participating centers it may be
too soon for definitive conclusions on the merits of MIPD.
The 10% absolute increase of POPF after MIPD warrants
further inquiry as this has been reported in small single center cohort
studies,34,35 but not in large registry studies14–16,18 or systematic
reviews.1,5,8 Because no differences in radiologic drainage or reoper-
ations were observed between groups, the higher POPF rate is likely
the result of prolonged drainage (ie, leaving the surgical drain in situ).
Besides the approach itself, 2 other factors could have influenced this
outcome; insufficient balance between groups at baseline (residual
confounding) or underreporting of POPF in the German and Dutch
registry data. First, residual confounding seems less likely, as OPD
control patients were retrieved from unselected populations, with less
than 5% MIPD use, and important risk factors associated with POPF
(BMI, pancreatic texture, vascular involvement)36,37 were controlled
for. Although pancreatic duct size was often missing, the result of a
secondary matched analysis on patients with available duct size was
not different from the primary analysis. Second, although the rates of
grade B/C POPF in the German and Dutch data on OPD were similar
(11%), the 2005 ISGPS definition26 can be interpreted in different
ways38 and POPF may not always be accurately scored postdischarge
in registry databases. Indeed, recent large retrospective single-center
studies on OPD have reported grade B/C POPF rates between 17%5,39
and 28%40 and prospective studies have reported rates between 17%41
and 25%.42 These proportions are closer to the 23% POPF rate after
MIPD found by this study. Moreover, the Indian PLOT trial found no
increase in grade B/C POPF between laparoscopic MIPD and OPD
(6% vs 13%, P ¼ 0.311) with an annual volume over 40 pancreatec-
tomy procedures and a total experience of over 150 MIPDs.19 Ulti-
mately, more (multicenter) randomized trials are needed to compare
POPF rates between MIPD and OPD.
This study has some limitations. First, we collected OPD
controls from validated nationwide surgical registries with < 5%
MIPD implementation and applied propensity score matching
to minimize confounding by indication (surgical case selection).
However, this type of bias can only be maximally avoided by
randomization. Second, because MIPD data were retrieved from
FIGURE 3. MainOutcomes and Sensitivity Analyses. Overview of the association between approach and primary (major morbidity)
and secondary (mortality, postoperative pancreatic fistulae) outcomes in primary and sensitivity analysis. Underlying data is
presented in Supplement 3, http://links.lww.com/SLA/B435.  Adjusted for: propensity score, age, sex, BMI, ASA, Charlson
comorbidity index, ECOG, tumor location, preoperative organ involvement, multivisceral resection, porto-mesenteric vein
resection and histological diagnosis. ASA indicates American Society of Anesthesiologists; BMI, body mass index; c, center; ECOG,
Eastern Cooperative Oncology Group; Excl., excluding; MV, multivariable; p, per; y, year.
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institutional databases and OPD data was retrieved from nationwide
registries, differences in data collection and follow-up methods may
have introduced information bias. Because major morbidity (requir-
ing reinterventions), mortality, and length of stay are hard outcomes,
this is less of a concern for the main study conclusions. Third, we
could not compare levels of estimated blood loss or grade A POPF
(ie, biochemical leak), because these variables were not recorded in
the nationwide registries. Blood loss, however, is not an essential risk
factor in the recent alternative fistula risk score (aFRS).36 Fourth, a
variety of centers with different settings (academic vs nonacademic)
and geographical characteristics were included. The result is sub-
stantial heterogeneity in preoperative workup, treatment strategies,
and postoperative management between centers. Although this
improves the external validity of the study, it reduces the accuracy
of measuring the association between the approach and outcomes.
This is the first international multicenter matched study on
MIPD versus OPD to date. A predefined study protocol was regis-
tered at clinicaltrials.gov to improve the study’s validity and centers
were offered anonymity to reduce reporting bias. The results give
valuable insights into the outcomes of MIPD in the early experience
of European centers performing at least 10 MIPDs per year. Conse-
quently, our results only apply to centers with similar characteristics.
Moving forward, there are 2 major determinants of successful
dissemination of MIPD: (i) the use of dedicated training programs
and (ii) total- and annual procedure-specific case volumes. First, as
previously shown in the Netherlands for laparoscopic distal pancrea-
tectomy (LAELAPS-1)43 and laparoscopic pancreatoduodenectomy
(LAELAPS-2),44 nationwide training programs can result in safe
implementation of minimally invasive pancreatic surgery. In addi-
tion, a reproducible Institutional Training and Fellowship program
for robot-assisted pancreatoduodenectomy, like the Pittsburgh exam-
ple, has been shown to produce excellent outcomes.10,45 For exam-
ple, their grade B/C POPF rate improved from 27.5% to 14.4% (P ¼
0.04) after the first 40 MIPDs. The LAELAPS-3 program was based
on the Pittsburgh program and is currently being used, including
Pittsburgh-based proctors, to implement robot-assisted MIPD within
the Dutch Pancreatic Cancer Group.46 Second, 2 recent US nation-
wide studies found a volume-outcome associations for MIPD and
defined a minimum volume cut-off of 22 to 25 MIPDs per year to
achieve comparable outcomes to OPD.47,48 In the current study, no
clear association between volume and POPF was found, but it should
be noted that only 6 of 14 centers performed more than 20MIPDs per
year and only one center performed more than 40 MIPDs per year.
Future studies with more centers reaching higher annual case-
volumes are therefore needed.
This study found that MIPD is associated with similar 30-day
majormorbidity,mortality, and length of stay, but longer operative times
and a 10% higher rate of grade B/C POPF compared with OPD. No
differences in outcomes were found between robot-assisted-, laparo-
scopic- and hybrid MIPD, with lower conversion rates after robot-
assistedMIPD, although this sub group analysiswas not the primary aim
of the current study. In contrast to prior expectations, this study did not
find the secondary benefits (eg, shorter hospital stays) to support the
immediate widespread implementation of MIPD. We conclude that
MIPD does not increase major morbidity or 30-day mortality in centers
performing at least 10 MIPDs per year. However, the impact of
anastomotic technique, higher annual case-volumes, and experience
on outcomes (eg, grade B/C POPF) should be addressed in (prospective)
studies before the true impact of MIPD can be established.
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